The agency’s letter to the Marlborough-based medical device company's (Nasdaq: HOLX) CEO, Stephen MacMillan, which was made public on Tuesday, said the FDA found that the company’s BioZorb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback